Literature DB >> 20443880

An operational perspective of challenging statistical dogma while establishing a modern, secure distributed data management and imaging transport system: the Pediatric Brain Tumor Consortium phase I experience.

Arzu Onar1, Uma Ramamurthy, Dana Wallace, James M Boyett.   

Abstract

The Pediatric Brain Tumor Consortium (PBTC) is a multidisciplinary cooperative research organization devoted to the study of correlative tumor biology and new therapies for primary central nervous system (CNS) tumors of childhood. The PBTC was created in 1999 to conduct early-phase studies in a rapid fashion in order to provide sound scientific foundation for the Children's Oncology Group to conduct definitive trials. The Operations and Biostatistics Center (OBC) of the PBTC is responsible for centrally administering study design and trial development, study conduct and monitoring, data collection and management as well as various regulatory and compliance processes. The phase I designs utilized for the consortium trials have accommodated challenges unique to pediatric trials such as body surface area (BSA)-based dosing in the absence of pediatric formulations of oral agents. Further during the past decade, the OBC has developed and implemented a state-of-the-art secure and efficient internet-based paperless distributed data management system. Additional web-based systems are also in place for tracking and distributing correlative study data as well as neuroimaging files. These systems enable effective communications among the members of the consortium and facilitate the conduct and timely reporting of multi-institutional early-phase clinical trials.

Entities:  

Mesh:

Year:  2009        PMID: 20443880      PMCID: PMC2877373          DOI: 10.1111/j.1752-8062.2009.00105.x

Source DB:  PubMed          Journal:  Clin Transl Sci        ISSN: 1752-8054            Impact factor:   4.689


  12 in total

1.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

Authors:  J O'Quigley; M Pepe; L Fisher
Journal:  Biometrics       Date:  1990-03       Impact factor: 2.571

2.  Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001).

Authors:  Susan M Blaney; James Boyett; Henry Friedman; Amar Gajjar; Russ Geyer; Marc Horowtiz; Daniel Hunt; Mark Kieran; Larry Kun; Roger Packer; Peter Phillips; Ian F Pollack; Michael Prados; Richard Heideman
Journal:  J Clin Oncol       Date:  2005-01-20       Impact factor: 44.544

3.  Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report.

Authors:  Ian F Pollack; Regina I Jakacki; Susan M Blaney; Michael L Hancock; Mark W Kieran; Peter Phillips; Larry E Kun; Henry Friedman; Roger Packer; Anu Banerjee; J Russell Geyer; Stewart Goldman; Tina Young Poussaint; Matthew J Krasin; Yanfeng Wang; Michael Hayes; Anthony Murgo; Susan Weiner; James M Boyett
Journal:  Neuro Oncol       Date:  2007-02-09       Impact factor: 12.300

Review 4.  Tissue collection for correlative studies in childhood cancer clinical trials: ethical considerations and special imperatives.

Authors:  Barry D Anderson; Peter C Adamson; Susan L Weiner; Mary S McCabe; Malcolm A Smith
Journal:  J Clin Oncol       Date:  2004-12-01       Impact factor: 44.544

5.  Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012.

Authors:  Tobey J MacDonald; Clinton F Stewart; Mehmet Kocak; Stewart Goldman; Richard G Ellenbogen; Peter Phillips; Deborah Lafond; Tina Young Poussaint; Mark W Kieran; James M Boyett; Larry E Kun
Journal:  J Clin Oncol       Date:  2008-02-20       Impact factor: 44.544

6.  Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study.

Authors:  Sridharan Gururangan; Christopher D Turner; Clinton F Stewart; Melinda O'Shaughnessy; Mehmet Kocak; Tina Young Poussaint; Peter C Phillips; Stewart Goldman; Roger Packer; Ian F Pollack; Susan M Blaney; Verena Karsten; Stanton L Gerson; James M Boyett; Henry S Friedman; Larry E Kun
Journal:  Clin Cancer Res       Date:  2008-02-15       Impact factor: 12.531

7.  Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004).

Authors:  Sridharan Gururangan; William P Petros; Tina Young Poussaint; Michael L Hancock; Peter C Phillips; Henry S Friedman; Lisa Bomgaars; Susan M Blaney; Larry E Kun; James M Boyett
Journal:  Clin Cancer Res       Date:  2006-03-01       Impact factor: 12.531

8.  Continual reassessment method vs. traditional empirically based design: modifications motivated by Phase I trials in pediatric oncology by the Pediatric Brain Tumor Consortium.

Authors:  Arzu Onar; Mehmet Kocak; James M Boyett
Journal:  J Biopharm Stat       Date:  2009       Impact factor: 1.051

9.  Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report.

Authors:  Alberto Broniscer; Sridharan Gururangan; Tobey J MacDonald; Stewart Goldman; Roger J Packer; Clinton F Stewart; Dana Wallace; Mary K Danks; Henry S Friedman; Tina Y Poussaint; Larry E Kun; James M Boyett; Amar Gajjar
Journal:  Clin Cancer Res       Date:  2007-11-15       Impact factor: 12.531

10.  Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma.

Authors:  Daphne A Haas-Kogan; Anuradha Banerjee; Mehmet Kocak; Michael D Prados; J Russell Geyer; Maryam Fouladi; Tracy McKnight; Tina Young Poussaint; Alberto Broniscer; Susan M Blaney; James M Boyett; Larry E Kun
Journal:  Neuro Oncol       Date:  2008-04-16       Impact factor: 12.300

View more
  3 in total

1.  A simulation-based comparison of the traditional method, Rolling-6 design and a frequentist version of the continual reassessment method with special attention to trial duration in pediatric Phase I oncology trials.

Authors:  Arzu Onar-Thomas; Zang Xiong
Journal:  Contemp Clin Trials       Date:  2010-03-15       Impact factor: 2.226

Review 2.  What we have learned: the impact of quality from a clinical trials perspective.

Authors:  Thomas J FitzGerald
Journal:  Semin Radiat Oncol       Date:  2012-01       Impact factor: 5.934

Review 3.  Collaborative cancer epidemiology in the 21st century: the model of cancer consortia.

Authors:  Michael R Burgio; John P A Ioannidis; Brett M Kaminski; Eric Derycke; Scott Rogers; Muin J Khoury; Daniela Seminara
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-09-17       Impact factor: 4.254

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.